Vertex Pharmaceuticals Competitors and Similar CompaniesClear all

Vertex Pharmaceuticals's competitors and similar companies include Eloxx Pharmaceuticals, Arcturus Therapeutics, 4D Molecular Therapeutics, Spirovant Sciences and Yumanity Therapeutics.

	Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines.	Eloxx Pharmaceuticals Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for rare and ultra-rare genetic diseases.	Arcturus Therapeutics Arcturus Therapeutics is a preclinical drug delivery and nucleic acid medicines company.	4D Molecular Therapeutics 4D Molecular Therapeutics is a company focused on creation of gene therapy products to cure genetic diseases.	Spirovant Sciences Spirovant Sciences is a company focused on the development of gene therapies for treating and curing cystic fibrosis and other lung diseases.	Yumanity Therapeutics Yumanity Therapeutics (formerly known as Proteostasis Therapeutics) is a biopharmaceutical company developing therapeutics to treat diseases caused by an imbalance in the proteostasis network.
Founding Date	Founding Date 1989	Founding Date 2013	Founding Date 2013	Founding Date 2013	Founding Date 2016	Founding Date 2014
Type	Type Public	Type Public	Type Public	Type Public	Type Private	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech genetics	Tags Healthcare drug development genetics pharma	Tags Healthcare biotech clinical research genetics surgical solutions	Tags Healthcare genetics pharma therapy	Tags Healthcare biotech drug development pharma
Locations	Locations Boston, US HQ St Leonards, AU Wien, AT Bruxelles, BE São Paulo, BR Toronto, CA Praha, CZ see more	Locations Waltham, US HQ Rehovot, IL	Locations San Diego, US HQ	Locations Emeryville, US HQ	Locations Philadelphia, US HQ	Locations Boston, US HQ
Employees	Employees 5,40013% increase	Employees 29	Employees 170	Employees 14013% increase	Employees 32	Employees 4434% decrease
Valuation ($)	Valuation ($) 126.3 b	Valuation ($) 2.2 m	Valuation ($) 538.4 m	Valuation ($) 817 m	Valuation ($) N/A	Valuation ($) 15.7 m
Financial
Revenue (est.)	Revenue (est.) $9.9b (FY, 2023)	Revenue (est.) N/A	Revenue (est.) $166.8m (FY, 2023)	Revenue (est.) $20.7m (FY, 2023)	Revenue (est.) N/A	Revenue (est.) $5.4m (FY, 2023)
Net income	Net income $3.6b (FY, 2023)	Net income ($36.1m) (FY, 2022)	Net income ($29.7m) (FY, 2023)	Net income ($100.8m) (FY, 2023)	Net income N/A	Net income ($14.1m) (FY, 2023)
Funding
Total funding raised	Total funding raised $ 2.4m	Total funding raised $ 30m	Total funding raised N/A	Total funding raised $ 100m	Total funding raised N/A	Total funding raised $ 82m